Ximelagatran

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

希美加群是一种直接凝血酶抑制剂，可以口服，仅通过抑制凝血酶的作用来发挥作用。希美加群在体内转化为活性剂美拉加群。

Ximelagatran, a direct thrombin inhibitor, can be taken orally and acts solely by inhibiting the actions of thrombin. Ximelagatran is converted to the active agent melagatran in vivo.(In Vitro):Ximelagatran is an orally administered direct thrombin inhibitor under development as an anticoagulant agent for prophylaxis against and treatment of thromboembolism. Ximelagatran is rapidly absorbed and quickly converted into its active form Melagatran, a reversible, active-site inhibitor of both free and clot-bound thrombin that has stable and reproducible pharmacokinetic properties. Initial studies have shown Ximelagatran to have good efficacy and safety in the prevention of venous thromboembolism after total knee or total hip replacement.

Ximelagatran is an orally administered direct thrombin inhibitor under development as an anticoagulant agent for prophylaxis against and treatment of thromboembolism. Ximelagatran is rapidly absorbed and quickly converted into its active form Melagatran, a reversible, active-site inhibitor of both free and clot-bound thrombin that has stable and reproducible pharmacokinetic properties. Initial studies have shown Ximelagatran to have good efficacy and safety in the prevention of venous thromboembolism after total knee or total hip replacement.

——

H 376-95 | H 376/95 | H 37695 | H-37695 | H37695 | EXANTA

Autophagy

Thrombin

H1 receptor| HCV

——

——

192939-46-1

473.574

C24H35N5O5

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (527.91 mM)

CCOC(=O)CN[C@H](C1CCCCC1)C(=O)N1CC[C@H]1C(=O)NCc1ccc(\C=N\NO)cc1

——

(-20℃)

With Ice Pack

≥ 2 years